EFPIA anti-counterfeiting pilot success could see industry recognise parallel traders as part of supply chain
This article was originally published in SRA
Mass serialisation is a viable way of strengthening the supply chain and protecting against counterfeit medicines, a pilot launched by the European Federation of Pharmaceutical Industries and Associations has shown1. Furthermore, roll-out of such a verification system could prompt industry to recognise parallel traders as part of the supply chain.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.